1. [1] Kamel AM, Moussa HS, Ebid GT, Bu RR, Bhatia KG. Synergistic effect of methyltetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphism as risk modifiers of pediatric acute lymphoblastic leukemia. J Egypt Natl Canc Inst 2007; 19: 96-105.

2. [2] Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet 2013; 381: 1943-1955. [DOI:10.1016/S0140-6736(12)62187-4]

3. [3] Robison LL. Late effects of acute lymphoblastic leukemia therapy in patients diagnosed at 0-20 years of age. Hematology Am Soc Hematol Educ Program 2011; 2011: 238-242. [DOI:10.1182/asheducation-2011.1.238] [PMID]

4. [4] Bahari G, Hashemi M, Naderi M, Taheri M. IKZF1 gene polymorphisms increased the risk of childhood acute lymphoblastic leukemia in an Iranian population. Tumour Biol 2016; 37: 9579-9586. [DOI:10.1007/s13277-016-4853-0] [PMID]

5. [5] Azimi F, Mortazavi Y, Alavi S, Khalili M, Ramazani A. Frequency of ITPA gene polymorphisms in Iranian patients with acute lymphoblastic leukemia and prediction of its myelosuppressive effects. Leuk Res 2015; 39: 1048-1054. [DOI:10.1016/j.leukres.2015.06.016] [PMID]

6. [6] Namazi S, Zareifar S, Monabati A, Ansari S, Karimzadeh I. Evaluating the effect of 3 glucocorticoid receptor gene polymorphisms on risk of relapse in 100 Iranian children with acute lymphoblastic leukemia: a case-control study. Clin Ther 2011; 33: 280-290. [DOI:10.1016/j.clinthera.2011.03.004] [PMID]

7. [7] Liu J, Zhou R, Zhang N, Rui J, Jin C. Biological function of a novel gene overexpressed in human hepatocellular carcinoma. Chin Med J (Engl) 2000; 113: 881-885.

8. [8] Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, Rui JA, et al. Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 2003; 22: 5060-5069. [DOI:10.1038/sj.onc.1206832] [PMID]

9. [9] Vergarajauregui S, Martina JA, Puertollano R. LAPTMs regulate lysosomal function and interact with mucolipin 1: new clues for understanding mucolipidosis type IV. J Cell Sci 2011; 124: 459-468. [DOI:10.1242/jcs.076240] [PMID] [PMCID]

10. [10] Liu XR, Zhou RL, Zhang QY, Zhang Y, Jin YY, Lin M, et al. Structure analysis and expressions of a novel tetratransmembrane protein, lysosoma-associated protein transmembrane 4 beta associated with hepatocellular carcinoma. World J Gastroenterol 2004; 10: 1555-1559. [DOI:10.3748/wjg.v10.i11.1555] [PMID] [PMCID]

11. [11] Li L, Shan Y, Yang H, Zhang S, Lin M, Zhu P, et al. Upregulation of LAPTM4B-35 promotes malignant transformation and tumorigenesis in L02 human liver cell line. Anat Rec (Hoboken) 2011; 294: 1135-1142. [DOI:10.1002/ar.21421] [PMID]

12. [12] Li L, Wei XH, Pan YP, Li HC, Yang H, He QH, et al. LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene 2010; 29: 5785-5795. [DOI:10.1038/onc.2010.303] [PMID]

13. [13] Xu Y, Liu Y, Zhou R, Meng F, Gao Y, Yang S, et al. LAPTM4B polymorphisms is associated with ovarian cancer susceptibility and its prognosis. Jpn J Clin Oncol 2012; 42: 413-419. [DOI:10.1093/jjco/hys026] [PMID]

14. [14] Kang Y, Yin M, Jiang W, Zhang H, Xia B, Xue Y, et al. Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma. Am J Surg 2012; 204: 677-683. [DOI:10.1016/j.amjsurg.2012.02.003] [PMID]

15. [15] Kasper G, Vogel A, Klaman I, Grone J, Petersen I, Weber B, et al. The human LAPTM4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression. Cancer Lett 2005; 224: 93-103. [DOI:10.1016/j.canlet.2004.10.004] [PMID]

16. [16] Yang H, Xiong F, Qi R, Liu Z, Lin M, Rui J, et al. LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma. J Surg Oncol 2010; 101: 363-369. [DOI:10.1002/jso.21489] [PMID]

17. [17] Zhang G, Liang Y, Huang Y, Chen Y, Zhou R. Elevated lysosome-associated protein transmembrane-4beta-35 is an independent prognostic marker in pancreatic carcinoma. J Int Med Res 2012; 40: 1275-1283. [DOI:10.1177/147323001204000406] [PMID]

18. [18] Zhou L, He XD, Cui QC, Zhou WX, Qu Q, Zhou RL, et al. Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett 2008; 264: 209-217. [DOI:10.1016/j.canlet.2008.01.025] [PMID]

19. [19] Meng F, Li H, Zhou R, Luo C, Hu Y, Lou G. LAPTM4B gene polymorphism and endometrial carcinoma risk and prognosis. Biomarkers 2013; 18: 136-143. [DOI:10.3109/1354750X.2012.752526] [PMID]

20. [20] Yang Y, Yang H, McNutt MA, Xiong F, Nie X, Li L, et al. LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep 2008; 20: 1077-1083.

21. [21] Xiao M, Jia S, Wang H, Wang J, Huang Y, Li Z. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer. J Cancer Res Clin Oncol 2013; 139: 661-667. [DOI:10.1007/s00432-012-1368-y] [PMID]

22. [22] Zhang M, Zhou R, Xu J, Zhang Q. Relationship Between LAPTM4B Gene Polymorphism and Susceptibility of Malignant Melanoma in Chinese Patients. Transl Oncol 2014; 7: 638-643. [DOI:10.1016/j.tranon.2014.07.001] [PMID] [PMCID]

23. [23] Hashemi M, Rezaei M, Narouie B, Simforoosh N, Basiri A, Ziaee SA, et al. Association between LAPTM4B gene polymorphism and prostate cancer susceptibility in an Iranian population. Mol Cell Oncol 2016; 3: e1169342. [DOI:10.1080/23723556.2016.1169342] [PMID] [PMCID]

24. [24] Hashemi M, Bahari G, Tabasi F, Markowski J, Malecki A, Ghavami S, et al. LAPTM4B gene polymorphism augments the risk of cancer: Evidence from an updated meta-analysis. J Cell Mol Med 2018; 22: 6396-6400. [DOI:10.1111/jcmm.13896] [PMID] [PMCID]

25. [25] Fan M, Liu Y, Zhou R, Zhang Q. Association of LAPTM4B gene polymorphism with breast cancer susceptibility. Cancer Epidemiol 2012; 36: 364-368. [DOI:10.1016/j.canep.2011.12.004] [PMID]

26. [26] Li X, Kong X, Chen X, Zhang N, Jiang L, Ma T, et al. LAPTM4B allele *2 is associated with breast cancer susceptibility and prognosis. PLoS One 2012; 7: e44916. [DOI:10.1371/journal.pone.0044916] [PMID] [PMCID]

27. [27] Yang H, Zhai G, Ji X, Xiong F, Su J, McNutt MA. Correlation of LAPTM4B polymorphisms with gallbladder carcinoma susceptibility in Chinese patients. Med Oncol 2012; 29: 2809-2813. [DOI:10.1007/s12032-012-0173-4] [PMID]

28. [28] Liu Y, Zhang QY, Qian N, Zhou RL. Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer. Ann Oncol 2007; 18: 311-316. [DOI:10.1093/annonc/mdl394] [PMID]

29. [29] Cheng XJ, Xu W, Zhang QY, Zhou RL. Relationship between LAPTM4B gene polymorphism and susceptibility of colorectal and esophageal cancers. Ann Oncol 2008; 19: 527-532. [DOI:10.1093/annonc/mdm469] [PMID]

30. [30] Wang B, Xu J, Zhou R, Zhang Q. Association of LAPTM4B gene polymorphism with nasopharyngeal carcinoma susceptibility in a Chinese population. Med Oncol 2013; 30: 470. [DOI:10.1007/s12032-013-0470-6] [PMID]

31. [31] Meng F, Song H, Luo C, Yin M, Xu Y, Liu H, et al. Correlation of LAPTM4B polymorphisms with cervical carcinoma. Cancer 2011; 117: 2652-2658. [DOI:10.1002/cncr.25833] [PMID]

32. [32] Li C, Zhou Q, Wang Y, Chen X, Yang X, Zhu D. [Relationship between LAPTM4B gene polymorphism and susceptibility of lung cancer]. Zhongguo Fei Ai Za Zhi 2006; 9: 109-112.

33. [33] Wang B, Wang S, Liang G, Xu J, Zhou R, Zhang Q. Association of lysosomal protein transmembrane 4 beta gene polymorphism with pancreatic carcinoma susceptibility in the Chinese population. Tumour Biol 2017; 39: 1010428317705518. [DOI:10.1177/1010428317705518] [PMID]

34. [34] Xia LZ, Yin ZH, Ren YW, Shen L, Wu W, Li XL, et al. The relationship between LAPTM4B polymorphisms and cancer risk in Chinese Han population: a meta-analysis. Springerplus 2015; 4: 179. [DOI:10.1186/s40064-015-0941-7] [PMID] [PMCID]

35. [1] Kamel AM, Moussa HS, Ebid GT, Bu RR, Bhatia KG. Synergistic effect of methyltetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphism as risk modifiers of pediatric acute lymphoblastic leukemia. J Egypt Natl Canc Inst 2007; 19: 96-105.

36. [2] Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet 2013; 381: 1943-1955. [DOI:10.1016/S0140-6736(12)62187-4]

37. [3] Robison LL. Late effects of acute lymphoblastic leukemia therapy in patients diagnosed at 0-20 years of age. Hematology Am Soc Hematol Educ Program 2011; 2011: 238-242. [DOI:10.1182/asheducation-2011.1.238] [PMID]

38. [4] Bahari G, Hashemi M, Naderi M, Taheri M. IKZF1 gene polymorphisms increased the risk of childhood acute lymphoblastic leukemia in an Iranian population. Tumour Biol 2016; 37: 9579-9586. [DOI:10.1007/s13277-016-4853-0] [PMID]

39. [5] Azimi F, Mortazavi Y, Alavi S, Khalili M, Ramazani A. Frequency of ITPA gene polymorphisms in Iranian patients with acute lymphoblastic leukemia and prediction of its myelosuppressive effects. Leuk Res 2015; 39: 1048-1054. [DOI:10.1016/j.leukres.2015.06.016] [PMID]

40. [6] Namazi S, Zareifar S, Monabati A, Ansari S, Karimzadeh I. Evaluating the effect of 3 glucocorticoid receptor gene polymorphisms on risk of relapse in 100 Iranian children with acute lymphoblastic leukemia: a case-control study. Clin Ther 2011; 33: 280-290. [DOI:10.1016/j.clinthera.2011.03.004] [PMID]

41. [7] Liu J, Zhou R, Zhang N, Rui J, Jin C. Biological function of a novel gene overexpressed in human hepatocellular carcinoma. Chin Med J (Engl) 2000; 113: 881-885.

42. [8] Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, Rui JA, et al. Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 2003; 22: 5060-5069. [DOI:10.1038/sj.onc.1206832] [PMID]

43. [9] Vergarajauregui S, Martina JA, Puertollano R. LAPTMs regulate lysosomal function and interact with mucolipin 1: new clues for understanding mucolipidosis type IV. J Cell Sci 2011; 124: 459-468. [DOI:10.1242/jcs.076240] [PMID] [PMCID]

44. [10] Liu XR, Zhou RL, Zhang QY, Zhang Y, Jin YY, Lin M, et al. Structure analysis and expressions of a novel tetratransmembrane protein, lysosoma-associated protein transmembrane 4 beta associated with hepatocellular carcinoma. World J Gastroenterol 2004; 10: 1555-1559. [DOI:10.3748/wjg.v10.i11.1555] [PMID] [PMCID]

45. [11] Li L, Shan Y, Yang H, Zhang S, Lin M, Zhu P, et al. Upregulation of LAPTM4B-35 promotes malignant transformation and tumorigenesis in L02 human liver cell line. Anat Rec (Hoboken) 2011; 294: 1135-1142. [DOI:10.1002/ar.21421] [PMID]

46. [12] Li L, Wei XH, Pan YP, Li HC, Yang H, He QH, et al. LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene 2010; 29: 5785-5795. [DOI:10.1038/onc.2010.303] [PMID]

47. [13] Xu Y, Liu Y, Zhou R, Meng F, Gao Y, Yang S, et al. LAPTM4B polymorphisms is associated with ovarian cancer susceptibility and its prognosis. Jpn J Clin Oncol 2012; 42: 413-419. [DOI:10.1093/jjco/hys026] [PMID]

48. [14] Kang Y, Yin M, Jiang W, Zhang H, Xia B, Xue Y, et al. Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma. Am J Surg 2012; 204: 677-683. [DOI:10.1016/j.amjsurg.2012.02.003] [PMID]

49. [15] Kasper G, Vogel A, Klaman I, Grone J, Petersen I, Weber B, et al. The human LAPTM4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression. Cancer Lett 2005; 224: 93-103. [DOI:10.1016/j.canlet.2004.10.004] [PMID]

50. [16] Yang H, Xiong F, Qi R, Liu Z, Lin M, Rui J, et al. LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma. J Surg Oncol 2010; 101: 363-369. [DOI:10.1002/jso.21489] [PMID]

51. [17] Zhang G, Liang Y, Huang Y, Chen Y, Zhou R. Elevated lysosome-associated protein transmembrane-4beta-35 is an independent prognostic marker in pancreatic carcinoma. J Int Med Res 2012; 40: 1275-1283. [DOI:10.1177/147323001204000406] [PMID]

52. [18] Zhou L, He XD, Cui QC, Zhou WX, Qu Q, Zhou RL, et al. Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett 2008; 264: 209-217. [DOI:10.1016/j.canlet.2008.01.025] [PMID]

53. [19] Meng F, Li H, Zhou R, Luo C, Hu Y, Lou G. LAPTM4B gene polymorphism and endometrial carcinoma risk and prognosis. Biomarkers 2013; 18: 136-143. [DOI:10.3109/1354750X.2012.752526] [PMID]

54. [20] Yang Y, Yang H, McNutt MA, Xiong F, Nie X, Li L, et al. LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep 2008; 20: 1077-1083.

55. [21] Xiao M, Jia S, Wang H, Wang J, Huang Y, Li Z. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer. J Cancer Res Clin Oncol 2013; 139: 661-667. [DOI:10.1007/s00432-012-1368-y] [PMID]

56. [22] Zhang M, Zhou R, Xu J, Zhang Q. Relationship Between LAPTM4B Gene Polymorphism and Susceptibility of Malignant Melanoma in Chinese Patients. Transl Oncol 2014; 7: 638-643. [DOI:10.1016/j.tranon.2014.07.001] [PMID] [PMCID]

57. [23] Hashemi M, Rezaei M, Narouie B, Simforoosh N, Basiri A, Ziaee SA, et al. Association between LAPTM4B gene polymorphism and prostate cancer susceptibility in an Iranian population. Mol Cell Oncol 2016; 3: e1169342. [DOI:10.1080/23723556.2016.1169342] [PMID] [PMCID]

58. [24] Hashemi M, Bahari G, Tabasi F, Markowski J, Malecki A, Ghavami S, et al. LAPTM4B gene polymorphism augments the risk of cancer: Evidence from an updated meta-analysis. J Cell Mol Med 2018; 22: 6396-6400. [DOI:10.1111/jcmm.13896] [PMID] [PMCID]

59. [25] Fan M, Liu Y, Zhou R, Zhang Q. Association of LAPTM4B gene polymorphism with breast cancer susceptibility. Cancer Epidemiol 2012; 36: 364-368. [DOI:10.1016/j.canep.2011.12.004] [PMID]

60. [26] Li X, Kong X, Chen X, Zhang N, Jiang L, Ma T, et al. LAPTM4B allele *2 is associated with breast cancer susceptibility and prognosis. PLoS One 2012; 7: e44916. [DOI:10.1371/journal.pone.0044916] [PMID] [PMCID]

61. [27] Yang H, Zhai G, Ji X, Xiong F, Su J, McNutt MA. Correlation of LAPTM4B polymorphisms with gallbladder carcinoma susceptibility in Chinese patients. Med Oncol 2012; 29: 2809-2813. [DOI:10.1007/s12032-012-0173-4] [PMID]

62. [28] Liu Y, Zhang QY, Qian N, Zhou RL. Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer. Ann Oncol 2007; 18: 311-316. [DOI:10.1093/annonc/mdl394] [PMID]

63. [29] Cheng XJ, Xu W, Zhang QY, Zhou RL. Relationship between LAPTM4B gene polymorphism and susceptibility of colorectal and esophageal cancers. Ann Oncol 2008; 19: 527-532. [DOI:10.1093/annonc/mdm469] [PMID]

64. [30] Wang B, Xu J, Zhou R, Zhang Q. Association of LAPTM4B gene polymorphism with nasopharyngeal carcinoma susceptibility in a Chinese population. Med Oncol 2013; 30: 470. [DOI:10.1007/s12032-013-0470-6] [PMID]

65. [31] Meng F, Song H, Luo C, Yin M, Xu Y, Liu H, et al. Correlation of LAPTM4B polymorphisms with cervical carcinoma. Cancer 2011; 117: 2652-2658. [DOI:10.1002/cncr.25833] [PMID]

66. [32] Li C, Zhou Q, Wang Y, Chen X, Yang X, Zhu D. [Relationship between LAPTM4B gene polymorphism and susceptibility of lung cancer]. Zhongguo Fei Ai Za Zhi 2006; 9: 109-112.

67. [33] Wang B, Wang S, Liang G, Xu J, Zhou R, Zhang Q. Association of lysosomal protein transmembrane 4 beta gene polymorphism with pancreatic carcinoma susceptibility in the Chinese population. Tumour Biol 2017; 39: 1010428317705518. [DOI:10.1177/1010428317705518] [PMID]

68. [34] Xia LZ, Yin ZH, Ren YW, Shen L, Wu W, Li XL, et al. The relationship between LAPTM4B polymorphisms and cancer risk in Chinese Han population: a meta-analysis. Springerplus 2015; 4: 179. [DOI:10.1186/s40064-015-0941-7] [PMID] [PMCID]